Answers are grounded in this paper and cite their sources.
Evaluates the inhibitory effects of engineered thionucleosides on growth in MCF-7 cells, suggesting therapeutic potential.
The MCF-7 cell line, a well-researched human breast cancer model, has significantly contributed to advancing our knowledge of breast cancer biology and innovating treatment approaches. A notable trait of MCF-7 cells is their responsiveness to estrogen. Research involving MCF-7 cells has yielded significant knowledge regarding hormone receptor signaling and the modes of operation of anti-estrogen treatments like tamoxifen. Furthermore, MCF-7 cells have served as a platform for investigating drug resistance and for identifying prospective anti-cancer agents [1]. Modified nitrogen bases 2-mercaptopurine, thioguanine, and nucleosides 6-thioguanosine and 2’-deoxy-6-thioguanosine, along with Desulfated_Aztreonam and 2-(Benzylsulfanyl)-1-hydroxyadenosine, were evaluated for their potential anticancer properties. The antiproliferative assay was utilized to examine the characteristics of MCF-7 cells. The findings indicated that 2-mercaptopurine exhibited notable efficacy against MCF-7 cells, resulting in a 40% inhibition of growth [4]. Treatment with nitrogen bases 2-mercaptopurine and 6-thioguanine, along with nucleosides 6-thioguanosine and 2’-deoxy-6-thioguanosine, may exhibit antibacterial properties against MCF-7. Our findings offer fresh perspectives on the cytotoxic efficacy of thiopurines and propose a justification for opting for mercaptopurine over thioguanine in addressing various bacterialinduced illnesses.
No takes yet. Share an insight, caveat, or question.
Elena Sergeyevna Petrova (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: